Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Nivolumab for relapsed or persistent hematological malignancies after allogeneic transplant
ACTRN12617000473369Phase 2Active, not recruiting
- Sponsor
- Melbourne Health
- Start
- Apr 2017
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of nivolumab in hematopoietic malignancies, sponsored by Melbourne Health. Primary endpoint: Safety of nivolumab post-allogeneic transplant. Started Apr 2017; status: active, not recruiting.
02
Drugs
03
Conditions
hematopoietic malignancies
Beyond the preview
Go deeper on ACTRN12617000473369.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ACTRN12617000473369.